GLP1R and Hypoglycemia: The blockade of DPP-4 (an enzyme expressed on the surface of various cellular types and in free circulating form in plasma) increases the half-life of two intestinal peptides: GLP-1 (glucagon-like peptide-1) and GIP (glucose–dependent insulinotropic polypeptide), and thereby stimulates insulin synthesis and decrease glucagon secretion, which leads to blood glucose reduction with low risk of hypoglycemia, a desirable feature in the treatment of patients with ACS [27].